21 min listen
CIRM-Funded Pipeline of Regenerative Therapies Advances
FromThe Bio Report
ratings:
Length:
21 minutes
Released:
Aug 2, 2017
Format:
Podcast episode
Description
A number of clinical successes and the U.S. Food and Drug Administration’s granting of designations that provide accelerated pathways to experimental therapies speaks to the progress of research funded by the California Institute for Regenerative Medicine. We spoke to Kevin McCormack, senior director of public communications and patient advocate outreach for CIRM, about the growing pipeline of therapies, the changing regulatory environment, and whether the institute will have a future beyond its existing funding.
Released:
Aug 2, 2017
Format:
Podcast episode
Titles in the series (100)
The Forces Bringing Disruptive Change to Healthcare: Scientific breakthroughs, innovations in technology, and the changing use of data are among the forces that are driving disruptive changes to healthcare. A new report from the IMS Institute for Healthcare Informatics highlights a number of these deve... by The Bio Report